12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Company News  |  Deals

BioDiem, Merck deal

BioDiem regained from Merck's Nobilon International B.V. unit worldwide rights, excluding Russia and the Commonwealth of Independent States (CIS), to BioDiem's live attenuated influenza vaccine (LAIV) technology. BioDiem said Merck returned rights as a result of the pharma's ongoing pipeline prioritization. Nobilon had exclusive, worldwide rights, excluding Russia, CIS and North America, from BioDiem and previously shared...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >